VBI Vaccines

109 articles with VBI Vaccines

• VBI Vaccines Announces Results of Annual General Meeting - June 09, 2021

  6/9/2021

  VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the voting results from its annual general meeting of shareholders held on June 9, 2021.

• VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021

  6/9/2021

  VBI Vaccines Inc. today announced that two abstracts featuring data from the Company’s prophylactic and therapeutic hepatitis B (HBV) candidates have been accepted for presentation at The Digital International Liver Congress™ 2021.

• VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM

  6/8/2021

  FDA’s Fast Track Designation for VBI-1901 underscores the significant and urgent unmet medical need for new therapies for recurrent glioblastoma (GBM) patients.

• VBI Vaccines to Participate in Upcoming Investor Conferences

  6/1/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in analyst-led fireside chats at the following upcoming investor conferences:

• VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures

  5/21/2021

  VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced an agreement to drawdown a $12 million second tranche under its previously announced debt financing facility with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the debt financing facility, dated May 22, 2021

• VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting

  5/20/2021

  - 12-month overall survival (OS) : 60% (n=6/10) in VBI-1901 + GM-CSF study arm compared to historical controls of ~30% 1 –­ 12-month OS not yet reached with VBI-1901 + AS01 B 2 - 6-month OS : 80%+ survival achieved across both study arms compared to historical controls of ~60% 1 - 2 partial tumor responses and 7 stable disease observations across both study arms - Full data to be highlighted in ASCO poster presentation June 4-8, 2021

• VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

  5/12/2021

  VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

• VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update

  5/10/2021

  Hepatitis B : FDA and EMA regulatory review of VBI’s 3-antigen prophylactic HBV vaccine candidate ongoing – U.S. PDUFA target action date November 30, 2021 COVID-19 : Initial data from ongoing Phase 1/2 study of VBI-2902, VBI’s monovalent COVID-19 vaccine candidate, expected by end of Q2 2021

• VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021

  5/3/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that two abstracts highlighting data from the pivotal Phase 3 program evaluating the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine candidate have been accepted for oral and poster presentation at the Canadian Liver Meeting 2021

• VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)

  4/28/2021

  - Publication title: “An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose” - Publication to be available on pre-print server, bioRxiv , and has been submitted for scientific journal peer-review

• VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit

  4/27/2021

  VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will discuss VBI’s coronavirus vaccine candidates in a virtual, analyst-led biotech investor summit hosted by National Securities Corporation

• VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research

  4/26/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced its abstract featuring data from PROTECT, a pivotal Phase 3 immunogenicity and safety study evaluating the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine candidate, has been accepted for oral presentation at the National Foundation for Infectious Diseases

• Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

  4/21/2021

  – New combination trial of an RNA-targeted therapeutic candidate and an HBV immunotherapeutic candidate aimed at delivering a functional cure for chronic hepatitis B infection –

• VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate 

  4/12/2021

  VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate   Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) VBI-2601 (BRII-179) was well-tolerated with no safety signals observed at both low- and high-dose levels

• VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference

  3/15/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference

• CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants

  3/10/2021

  Up to $33m of funding will support development of VBI’s enveloped virus-like particle (eVLP) vaccine candidates against COVID-19 variants of concern. Phase 1 clinical study of VBI’s eVLP vaccine candidate, VBI-2905, targeting the B.1.351 variant, anticipated to initiate mid-year 2021.

• VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

  3/9/2021

  - Initial data from Phase 1 of the study expected by the end of Q2 2021, subject to rate of enrollment - Adaptive Phase 1/2 study supported by previously announced contribution from Strategic Innovation Fund of Canadian Government of up to CAD$56 million - Initiation of Phase 1/2 study of pan-coronavirus vaccine candidate, VBI-2901, anticipated later in 2021

• VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021

  3/2/2021

  FDA and EMA regulatory review of VBI’s 3-antigen HBV vaccine candidate ongoing – U.S. PDUFA target action date November 30, 2021 Initiation of the first Phase 1/2 study of VBI-2902, VBI’s monovalent COVID-19 vaccine candidate, expected in Q1 2021, with the anticipated start of a Phase 1/2 study of VBI-2901, VBI’s pan-coronavirus vaccine candidate, expected later in 2021

• VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference

  3/1/2021

  VBI Vaccines to Present at the Raymond James 42 nd Annual Institutional Investors Conference

• VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine

  2/2/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its filing of the Biologics License Application (BLA) for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate for the prevention of infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.